Jeff Castelli Biography and Net Worth

Dr. Castelli joined Amicus in July 2005 and currently serves as Chief Development Officer. He has over 20 years of experience in the Biotech and Orphan Drug industry, focused on rare disease research and development of medicines from discovery through market authorization. In his current capacity, he provides strategic leadership across all R&D activities, including direct oversight of Science, Clinical Research, and Medical Affairs. Previously at Amicus he has had responsibility for a number of different functions including program management, portfolio planning and the gene therapy business. Prior to joining Amicus, Dr. Castelli was a healthcare strategy consultant at Health Advances LLC and worked in business development at Neose Pharmaceuticals Inc. He received a B.S. from West Chester University and a Ph.D. from the University of Pennsylvania, and is an author on numerous publications and patents in the field of rare disease drug development.

What is Jeff Castelli's net worth?: The estimated net worth of Jeff Castelli is at least $3.70 million as of December 19th, 2023. Dr. Castelli owns 359,736 shares of Amicus Therapeutics stock worth more than $3,698,086 as of April 27th. This net worth estimate does not reflect any other assets that Dr. Castelli may own. Additionally, Dr. Castelli receives an annual salary of $709,640.00 as Insider at Amicus Therapeutics. Learn More about Jeff Castelli's net worth.
How old is Jeff Castelli?: Dr. Castelli is currently 52 years old. There are 5 older executives and no younger executives at Amicus Therapeutics. The oldest executive at Amicus Therapeutics is Mr. Simon Nicolas Reade Harford, Chief Financial Officer, who is 64 years old. Learn More on Jeff Castelli's age.
What is Jeff Castelli's salary?: As the Insider of Amicus Therapeutics, Inc., Dr. Castelli earns $709,640.00 per year. There are 2 executives that earn more than Dr. Castelli. The highest earning executive at Amicus Therapeutics is Mr. Bradley L. Campbell M.B.A., CEO, President & Director, who commands a salary of $984,090.00 per year. Learn More on Jeff Castelli's salary.
How do I contact Jeff Castelli?: The corporate mailing address for Dr. Castelli and other Amicus Therapeutics executives is 1 Cedar Brook Drive, Cranbury NJ, 08512. Amicus Therapeutics can also be reached via phone at (215) 921-7600 and via email at [email protected]. Learn More on Jeff Castelli's contact information.
Has Jeff Castelli been buying or selling shares of Amicus Therapeutics?: Jeff Castelli has not been actively trading shares of Amicus Therapeutics during the last ninety days. Most recently, Jeff Castelli sold 17,500 shares of the business's stock in a transaction on Tuesday, December 19th. The shares were sold at an average price of $13.25, for a transaction totalling $231,875.00. Following the completion of the sale, the insider now directly owns 359,736 shares of the company's stock, valued at $4,766,502. Learn More on Jeff Castelli's trading history.
Who are Amicus Therapeutics' active insiders?: Amicus Therapeutics' insider roster includes Lynn Bleil (Director), Bradley Campbell (CEO), Bradley Campbell (CEO), Jeff Castelli (Insider), David Clark (Insider), John Crowley (Chairman Emeritus), Margaret Mcglynn (Director), Samantha Prout (Insider), Michael Raab (Director), Ellen Rosenberg (Insider), Ellen Rosenberg (Insider), and Burke Whitman (Director). Learn More on Amicus Therapeutics' active insiders.
Are insiders buying or selling shares of Amicus Therapeutics?: During the last year, insiders at the biopharmaceutical company sold shares 42 times. They sold a total of 526,511 shares worth more than $6,805,375.39. The most recent insider tranaction occured on March, 5th when Director Margaret G Mcglynn sold 7,500 shares worth more than $100,500.00. Insiders at Amicus Therapeutics own 2.1% of the company. Learn More about insider trades at Amicus Therapeutics.
Information on this page was last updated on 3/5/2024.

Jeff Castelli Insider Trading History at Amicus Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/19/2023	Sell	17,500	$13.25	$231,875.00	359,736
6/22/2015	Sell	18,981	$13.94	$264,595.14
6/15/2015	Sell	7,377	$14.17	$104,532.09
6/8/2015	Sell	17,312	$12.87	$222,805.44
5/11/2015	Sell	10,000	$10.84	$108,400.00
4/1/2015	Sell	9,489	$10.69	$101,437.41
1/5/2015	Sell	4,667	$9.00	$42,003.00
11/25/2014	Sell	8,103	$8.00	$64,824.00
10/3/2014	Sell	8,552	$7.00	$59,864.00

Jeff Castelli Buying and Selling Activity at Amicus Therapeutics

Amicus Therapeutics Company Overview

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Today's Range

Now: $10.28

$10.11

$10.32

50 Day Range

MA: $11.95

$10.17

$13.85

2 Week Range

Now: $10.28

$9.70

$14.57

Volume

1,714,609 shs

Average Volume

2,662,181 shs

Market Capitalization

$3.04 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.75

Better than Bitcoin? The Biotech Stock with 46,751% Potential

From Behind the Markets | Ad

4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.

Get the name of the stock here >>>

Jeff Castelli Biography and Net Worth

What is Jeff Castelli's net worth?

How old is Jeff Castelli?

What is Jeff Castelli's salary?

How do I contact Jeff Castelli?

Has Jeff Castelli been buying or selling shares of Amicus Therapeutics?

Who are Amicus Therapeutics' active insiders?

Are insiders buying or selling shares of Amicus Therapeutics?